Incretin‐based therapy exerts effects such as reducing body weight (BW) by influencing appetite in the brain [143] as shown in a clinical trial with semaglutide vs. placebo [144] Additionally, incretin‐based therapy decreases adipose tissue mass and enhances EC vasodilation, as evidenced by a clinical trial with exenatide in male patients with hypertension and other cardiovascular complications associated with obesity and T2D [145]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.